Veradigm (NASDAQ:MDRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Veradigm (NASDAQ:MDRXFree Report) in a research report report published on Monday morning. The firm issued a hold rating on the software maker’s stock.

Veradigm Stock Down 1.8 %

MDRX stock opened at $9.24 on Monday. Veradigm has a 52 week low of $5.01 and a 52 week high of $14.09. The business has a 50-day simple moving average of $9.63 and a 200 day simple moving average of $8.96.

Institutional Investors Weigh In On Veradigm

A number of large investors have recently modified their holdings of MDRX. Innealta Capital LLC bought a new stake in shares of Veradigm during the 2nd quarter valued at approximately $38,000. TFO Wealth Partners LLC grew its stake in shares of Veradigm by 105,280.0% during the fourth quarter. TFO Wealth Partners LLC now owns 5,269 shares of the software maker’s stock worth $52,000 after buying an additional 5,264 shares during the last quarter. Meadow Creek Wealth Advisors LLC acquired a new position in shares of Veradigm during the first quarter worth $83,000. Forest Hill Capital LLC bought a new position in shares of Veradigm in the 4th quarter valued at $210,000. Finally, Campbell & CO Investment Adviser LLC boosted its holdings in shares of Veradigm by 5.7% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 42,113 shares of the software maker’s stock valued at $442,000 after acquiring an additional 2,263 shares in the last quarter.

About Veradigm

(Get Free Report)

Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

Read More

Analyst Recommendations for Veradigm (NASDAQ:MDRX)

Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.